Cargando…

Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study

OBJECTIVE: To examine associations between maternal use of cough medications containing dextromethorphan (DM) without guaifenesin (glyceryl guaiacolate (GG)) (‘DM alone’), GG without DM (‘GG alone’) or DM +GG and major birth defects in offspring. DESIGN: Population-based case–control study. SETTING:...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yanyan, Rhoads, Anthony, Burns, Trudy, Carnahan, Ryan M, Conway, Kristin M, Werler, Martha M, Mitchell, Allen, Romitti, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718348/
http://dx.doi.org/10.1136/bmjopen-2021-053604
_version_ 1784624705340178432
author Cao, Yanyan
Rhoads, Anthony
Burns, Trudy
Carnahan, Ryan M
Conway, Kristin M
Werler, Martha M
Mitchell, Allen
Romitti, Paul
author_facet Cao, Yanyan
Rhoads, Anthony
Burns, Trudy
Carnahan, Ryan M
Conway, Kristin M
Werler, Martha M
Mitchell, Allen
Romitti, Paul
author_sort Cao, Yanyan
collection PubMed
description OBJECTIVE: To examine associations between maternal use of cough medications containing dextromethorphan (DM) without guaifenesin (glyceryl guaiacolate (GG)) (‘DM alone’), GG without DM (‘GG alone’) or DM +GG and major birth defects in offspring. DESIGN: Population-based case–control study. SETTING: The multisite, US National Birth Defects Prevention Study. PARTICIPANTS: Mothers of 1644 children with neural tube defects (NTDs), 15 110 with non-NTDs, and 10 671 control children without a birth defect diagnosis. MAIN OUTCOME MEASURES: ORs and 95% CIs. RESULTS: For NTD analysis, 1.7% of mothers of case children and 1.2% of mothers of control children reported using DM alone, 1.1% and 0.6% GG alone, and 0.4% and 0.2% DM +GG. Respective percentages for non-NTD analysis were 2.2% and 1.9% for DM alone, 1.7% and 1.6% for GG alone, and 0.5% and 0.4% for DM +GG. For all NTDs and subtypes, adjusted OR estimates for DM alone were near the null with 95% CIs that included 1.0. Estimates (95% CI) were 1.8 (1.0 to 3.3) for GG alone and 1.8 (0.6 to 4.8) for DM +GG with all NTDs and 2.2 (1.1 to 4.3) for GG alone with spina bifida. Of the 45 adjusted OR estimates for non-NTDs, 39 ranged from 0.5 to 1.6 with 95% CIs that included 1.0. Near twofold or higher estimates (95% CI) were observed for the remainder and included 1.9 (1.0 to 3.7) for hydrocephalus, 2.9 (1.3 to 6.5) for atrioventricular septal defect and 1.8 (1.1 to 3.0) for transverse limb deficiency with DM alone; 2.1 (1.1 to 4.0) for small intestinal atresia/stenosis and 2.1 (0.9 to 4.5) for omphalocele with GG alone; and 3.2 (1.5 to 6.9) for gastroschisis with DM +GG. CONCLUSIONS: Maternal use of medications containing DM alone, GG alone or DM +GG showed positive associations with a small number of birth defects. These observations, which should be interpreted with caution due to small proportions of exposed mothers, may represent true signals or chance findings and warrant evaluation in future studies.
format Online
Article
Text
id pubmed-8718348
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-87183482022-01-04 Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study Cao, Yanyan Rhoads, Anthony Burns, Trudy Carnahan, Ryan M Conway, Kristin M Werler, Martha M Mitchell, Allen Romitti, Paul BMJ Open Epidemiology OBJECTIVE: To examine associations between maternal use of cough medications containing dextromethorphan (DM) without guaifenesin (glyceryl guaiacolate (GG)) (‘DM alone’), GG without DM (‘GG alone’) or DM +GG and major birth defects in offspring. DESIGN: Population-based case–control study. SETTING: The multisite, US National Birth Defects Prevention Study. PARTICIPANTS: Mothers of 1644 children with neural tube defects (NTDs), 15 110 with non-NTDs, and 10 671 control children without a birth defect diagnosis. MAIN OUTCOME MEASURES: ORs and 95% CIs. RESULTS: For NTD analysis, 1.7% of mothers of case children and 1.2% of mothers of control children reported using DM alone, 1.1% and 0.6% GG alone, and 0.4% and 0.2% DM +GG. Respective percentages for non-NTD analysis were 2.2% and 1.9% for DM alone, 1.7% and 1.6% for GG alone, and 0.5% and 0.4% for DM +GG. For all NTDs and subtypes, adjusted OR estimates for DM alone were near the null with 95% CIs that included 1.0. Estimates (95% CI) were 1.8 (1.0 to 3.3) for GG alone and 1.8 (0.6 to 4.8) for DM +GG with all NTDs and 2.2 (1.1 to 4.3) for GG alone with spina bifida. Of the 45 adjusted OR estimates for non-NTDs, 39 ranged from 0.5 to 1.6 with 95% CIs that included 1.0. Near twofold or higher estimates (95% CI) were observed for the remainder and included 1.9 (1.0 to 3.7) for hydrocephalus, 2.9 (1.3 to 6.5) for atrioventricular septal defect and 1.8 (1.1 to 3.0) for transverse limb deficiency with DM alone; 2.1 (1.1 to 4.0) for small intestinal atresia/stenosis and 2.1 (0.9 to 4.5) for omphalocele with GG alone; and 3.2 (1.5 to 6.9) for gastroschisis with DM +GG. CONCLUSIONS: Maternal use of medications containing DM alone, GG alone or DM +GG showed positive associations with a small number of birth defects. These observations, which should be interpreted with caution due to small proportions of exposed mothers, may represent true signals or chance findings and warrant evaluation in future studies. BMJ Publishing Group 2021-12-30 /pmc/articles/PMC8718348/ http://dx.doi.org/10.1136/bmjopen-2021-053604 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Cao, Yanyan
Rhoads, Anthony
Burns, Trudy
Carnahan, Ryan M
Conway, Kristin M
Werler, Martha M
Mitchell, Allen
Romitti, Paul
Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study
title Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study
title_full Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study
title_fullStr Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study
title_full_unstemmed Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study
title_short Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study
title_sort maternal use of cough medications during early pregnancy and selected birth defects: a us multisite, case–control study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718348/
http://dx.doi.org/10.1136/bmjopen-2021-053604
work_keys_str_mv AT caoyanyan maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT rhoadsanthony maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT burnstrudy maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT carnahanryanm maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT conwaykristinm maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT werlermartham maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT mitchellallen maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy
AT romittipaul maternaluseofcoughmedicationsduringearlypregnancyandselectedbirthdefectsausmultisitecasecontrolstudy